AstraZeneca is currently progressing Phase II/III trials in the UK for its potential COVID-19 vaccine, AZD1222, with data expected from these expected in August or September.
However, the company is also working to get large-scale clinical trials underway in the US and has partnered with IQVIA to aid the process.
The partnership has been agreed as part of ‘Operation Warp Speed’, a US government initiative that aims to have a vaccine for COVID-19 ready for the beginning of 2021.
IQVIA will create an ‘expansive subject study’ that will begin gathering participants this summer.
The company will utilize its Virtual Trial solutions in order to conduct the clinical studies of the vaccine.
This decentralized clinical trial model allows for a remote study or a hybrid study, wherein a traditional clinical trial setting is augmented with telemedicine, home health visits and digital devices.
The service also includes the availability for the digital platforms to be available in multiple languages and a ‘concierge digital experience’, which includes live chat and 24/7 patient support.
Few further details were provided on the partnership, except that the service will allow for a ‘faster delivery’ of clinical studies for AZ’s vaccine.
